Xenoscope 5mm and 10mm disposable HD Laparoscopes
The Xenocor fog-proof HD laparoscope with integrated light-source is used for minimally-invasive, abdominal and thoracic procedures. These innovations in technology benefit patients, facilities and providers because they reduce a number of bio-hazard risk factors, minimize common visualization challenges and eliminate capital expense and reprocessing costs associated with laparoscopic surgery.
XENOBOX HD IMAGE OPTIMIZER
The Xenobox is a compact reusable unit which serves as the power supply for the Xenoscope. It is a robust central video processor and universal adapter that integrates seamlessly into any HD monitor or existing hospital video system.
The Xenobox, the 5mm articulating and 10mm Xenoscopes are patent protected and FDA cleared and the Xenobox and the10mm scope have also been CE Marked.
XENOBOX HD IMAGE OPTIMIZER
The Xenobox is a compact reusable unit which serves as the power supply for the Xenoscope. It is a robust central video processor and universal adapter that integrates seamlessly into any HD monitor or existing hospital video system.
The Xenobox, the 5mm articulating and 10mm Xenoscopes are patent protected and FDA cleared and the Xenobox and the10mm scope have also been CE Marked.
XENOSCOPE
Product Advantages
Easy To Use
- Lightweight
- Compatible with all HD Monitors, TV’s, Tablets and existing O.R. imaging infustructure
- No capital expenditure or service contracts
- No cleaning, inspecting or re-processing
- Ready for use right off the shelf
Consistent HD Visualization
- Designed to provide HD 1080P image with Clearview Technology (TM)
- Integrated light source and digital HD camera utilizing plug and play technology
- Fog proof
- Consistent image through electrocautery smoke
- Manual focus to improve workflow
Safe
- Non-conducting shaft removes the risk of electrosurgical arcing
- Low temperature Illumination removes risk of scope burns
- Disposable single use device helps reduce the risk of disease transmission
- Fog proof for consistent image quality
Disposable
- Designed to help reduce the risk of disease transmission
- Saves time and expense of costly cleaning and sterilization
- No capital expenditure to evaluate and use
Who We Are
Our Leadership
CEO Xenocor
Founder
Chief Engineer
VP – Sales and Marketing
Xenocor Founding Story:
Our Board
U.S. 1-844-XENOCOR
Customer Relations
630 Komas Dr. Suite 200
Salt Lake City UT 84108
Speak With Us Today!
John Langell, Founder
Evan Kelso, CEO Xenocor
Evan Kelso brings 20 years of successful experience in clinical sales and marketing to lead the commercialization efforts for the Xenocor product line.
During his tenure in the industry he worked for several major healthcare companies including United States Surgical/Medtronic to garner extensive and broad clinical training in multiple surgical fields. At DePuy Synthes Spine he had advanced training to specialize and deepen his clinical knowledge developing a full understanding of the complexity and working relationships for the technologies and processes in the neurospine market. His job was to introduce innovative products and solutions into the operating room to advance surgical procedures, optimizing outcomes for patients.
Through working very closely with doctors and hospital administrators, he developed comprehensive insider-knowledge for best practices in hospital management and procurement operations, surgical procedures and OR functioning, business and financial analytics/revenue stream, as well as a keen understanding of the product landscape and competitive arena. These insights, along with key relationships he has nurtured, will be brought to bear, ensuring the success of the Xenocor product line.
In addition, he is properly trained and clinically proficient to support the specialties of general, trauma, GYN, Bariatrics, laparoscopy, CVT and neurospine surgical processes and procedures.
Prior to his leadership position at Xenocor, he founded Vortex Medical, a national imaging focused disposition company.
Dinesh Patel, Board Member
founded vSpring Capital ($400 million under management) in 2000 and has been a founding managing director till October 2014.
Prior to vSpring Capital, Dr. Patel was an active angel investor in over 20 biotech and technology companies. From 1985 – 1999 Dr. Patel served as Co-Founder, Chairman of The Board of Directors and President & CEO of TheraTech, Inc., a biotechnology company which he took public and eventually sold to Watson Pharmaceuticals (now Actavis) for $350 million. From 1999 to 2004 he was the Founder, Chairman, President & CEO of Ashni Naturaceuticals, Inc., a company that specializes in the research, development and marketing of clinically tested and patent-protected naturaceutical products. In 1999, Dr. Patel co-founded and was the Chairman of Salus Therapeutics, Inc., a biotechnology company focused on the research and development of nucleic acid-based therapeutics, including antisense and gene therapy drugs. He currently holds 15 US Patents and Foreign Counterparts.
Dr. Patel also served on the board of Mediconnect Global, a worldwide leader in medical record retrieval, digitization, and one of the largest cloud based health information exchange. In March 2012, Mediconnect was acquired by Verisk Analytics (VRSK) for over $377 million.
Dr. Patel serves on several non-profit boards, and has won numerous awards including; 2013 Willem J Kolff Lifetime Achievement Award, the 2011 Father of the Year, 2010 Utah Youth Village Helping Hand Award, 2006 Utah Technology Council Hall of Fame Inductee, 2006 Ellis Island Medal of Honor, US Small Business Administration’s Business Achiever Award, Scientific and Technology Award (State of Utah), Entrepreneur of the Year Award (Mountain West Venture Group) and Scientific and Technology Development Pioneer of Progress Award to name a few. He is also a charter member of The Indus Entrepreneurs (TiE).
Dr. Patel served as co-chair of Governor Huntsman’s transition and he served as the Chairman of the USTAR Governing Authority board from 2006-2014. He is a member of the Life Sciences and Management Board at the University of Pennsylvania , on the University of Michigan’s President’s Advisory Group and on the University of Utah’s National Advisory Council.
Born and raised in Zambia, Africa, Dr. Patel received his bachelor’s degree in Pharmacy at Gujarat University located in Ahmedabad, Gujarat, India, his master’s degree from the Philadelphia College of Pharmacy and his Ph.D. in Physical Pharmacy from the University of Michigan.
Dr. Patel led the firm’s investments in Altea Therapeutics, American Academy, Athena Feminine Technologies, Axial Biotech, Coherex Medical, Exagen Diagnostics, Mirabilis Medica, Numira Biosciences, Lineagen, NanaMR, Q Therapeutics, Scintila, ZARS Pharma and Salus Therapeutics which was acquired by Genta (NASDAQ: GNTA) for $30 million.
Lane Brooks, Chief Engineer
Tony Watson, VP - Sales and Marketing
Tony Watson spent 16 years in marketing and sales for medical device companies including Medtronic/Covidien, fine-tuning his understanding of the complex relationships between providers, facilities and vendors. He has extensive go-to-market experience, most recently having developed and implemented a successful marketing strategy, which introduced a product and created a new market for the start-up TTCMed.
He is now focused on getting the Xenocor product portfolio into the broader market in order to lower costs and simplify procedural flow for hospitals, but ultimately to increase access to high quality laparoscopic care. Tony received his MBA from Carlson School of management at the University of Minnesota.
Jim Hogan, Board Member
Troy D'Ambrosio
Board Member
Troy D’Ambrosio is co-founder, officer and director of multiple start-up companies, which attracted over $500 million in capital; include founding Transworld Telecommunications which was sold to Sprint in 1996, Convergence Communications which was sold to Lockheed Martin in 2005and EPM Mining Ventures listed on the Toronto Venture Exchange. He has served as the VP of Investor Relations and Corporate Communication for American Stores Company, an NYSE listed company, and the Director of Mutual Fund Operations for Wasatch Advisors. He graduated from the University of Utah in 1982 and was named the Ernst & Young Entrepreneur of the Year in 2000, a v100 Technology leader in 2008 and Best in State Educational Administrator in 2009.
Shawn Fojtik, Board Member
His experience includes devices for cardiology, interventional radiology & oncology, electrophysiology, and other procedures.
Distal Access’s team commercialized the SPINR high-performance guidewire controller then sold it to Merit Medical in 2015. Then, Distal developed the Resectr, launched it remove uterine polyps in July 2016, and sold it to Boston Scientific in November 2016.
Control Medical’s award-winning platform is used to remove blood clots during heart attack, peripheral vascular disease, deep vein thrombosis, and stroke.
CIRCA Scientific commercialized a self-expanding rapid-sensing catheter-probe that achieved profitability in under 3 years from financing.
Shawn is an Adjunct Assistant Professor of Surgery at the University of Utah with a BS from the University of Illinois and a MA from Harvard University.